UnitedHealth acquires DaVita Medical Group for $4.9bn

By Catherine Sturman
Following on from the merger of CVS Health and Aetna, DaVita Medical Group’s clinics have been acquired by UnitedHealth for $4.9bn. Subject to regulat...

Following on from the merger of CVS Health and Aetna, DaVita Medical Group’s clinics have been acquired by UnitedHealth for $4.9bn. Subject to regulatory approval, the deal will see DaVita become part of United’s Optum unit, encompassing its outpatient operations, covering homecare, consulting, clinics and its pharmaceutical operations. 

The merger of CVS Health and Aetna highlights how the US healthcare industry is continuing to transform in the face of political uncertainties, alongside the utilisation of new technologies to drive down increasing healthcare costs and provide increased value to patients.

Through the acquisition, DaVita’s 2,000 strong team will merge with UnitedHealth’s 30,000 strong workforce, who will work to support DaVita’s 300 clinics and over 1.5mn patients across six US states.

Related stories

With a $5mn operating loss in its third quarter, DaVita aims to further undergo “significant stock repurchases,” within its operations following the close of the deal, all of which will further improve its future in the healthcare industry.

“This acquisition fits right into UNH’s [UnitedHealth Group’s] plan to direct patients from high-cost hospital settings to lower-cost urgent care and outpatient facilities and will leverage its vast physician footprint to accelerate that change,” commented Raymond James analyst Michael J.

One company sure to benefit from the acquisition is Berkshire Hathaway, which holds a 20% stake in the company. The deal has seen Berkshire gain over $231mn, and has seen DaVita shares rise significantly upon the announcement.

Share

Featured Articles

McKinsey: Women More Likely to die of Heart Attack Than Men

McKinsey Health Institute's Lucy Pérez says cardiovascular disease top killer of women yet physicians don't know their heart attack symptoms are different

Novo Nordisk Buys $1bn Cardior in CardioVascular Move

As Novo Nordisk expands into heart medicines, we profile the Danish pharma giant who in 1923 was the first to make insulin commercially available

Shoddy Chinese Syringes Sees BD Ramp-up Production

Becton Dickinson – a major supplier of syringes – said it has upped manufacturing in its US facilities after FDA warning on China-made products

AI Tool 'Picks up Early-stage Breast Cancers Doctors Missed'

Technology & AI

AstraZeneca Buys $2bn Fusion in Next-gen Cancer Drugs Move

Medical Devices & Pharma

Eli Lilly and Amazon Pharmacy Partner on Drugs Delivery

Digital Healthcare